Bioxodes

Wishing you all a joyful holiday season from the entire Bioxodes team! 🎄 We are incredibly grateful for your support and the progress we've made together this past year. We eagerly anticipate what 2025 has in store for us! #bioxodes #christmas2024 #biotech #stroke #clinicaldevelopment

✨ Bioxodes meets a milestone – 16th patient enrolled in BIOX-101 trial. ✨ Bioxodes has enrolled patient nr 16 in a clinical trial with BIOX-101 in hemorrhagic stroke, marking a major milestone that will trigger an interim data analysis. Across 10 stroke units in Belgium, we are testing BIOX-101, a therapy designed to limit the damage from intracerebral hemorrhagic stroke (ICH), developed from tick saliva. ICH is an often deadly disease for which there is no available medication. It causes some 40% of all stroke-related deaths, even though it makes up only 13% of all strokes. We expect our interim report by March 2025, an important next step in our mission of offering a breakthrough hope for hemorrhagic stroke patients. Full press release 👉 https://lnkd.in/d_rW9auU BioWin Brussels South Charleroi BioPark #strokecare #voiceofstroke #clinicaltrials #biotech #healthcare #innovation

🔺 MEDIA ARTICLE 🔻 Promising advancements in the treatment of hemorrhagic stroke An insightful interview with our CMO Hans Warrinnier was recently featured in Doctissimo.fr, where journalist Magali Régnier-Ratuvou explored the groundbreaking potential of BIOX-101 for hemorrhagic stroke. This article sheds light on the urgent need for innovative treatments for this life-threatening condition and how BIOX-101 could help minimize long-term damage and improve outcomes for patients. 🧠 Derived from the saliva of ticks, #BIOX-101 combines anti-clotting and anti-inflammatory properties without increasing the risk of bleeding—a critical advantage in stroke management. As shared in the interview, Bioxodes is paving the way for a new therapeutic era, with its current Phase 2a trial already underway across 10 specialized stroke centers in Belgium.  A special thank you to Magali Régnier-Ratuvou and the Doctissimo.fr team for the thoughtful and engaging collaboration on this article. It’s a privilege to share Bioxodes’ mission and innovations with a wider audience. 📌 Read the full article here (in French) 👉 https://lnkd.in/euwQE3EU 📌 Learn more about Bioxodes and their mission 👉 www.bioxodes.com #Biotech #Innovation #StrokeTreatment #LifeSciences #strokecare

🤔 Curious about how a tick molecule can potentially rescue lives after a hemorrhagic stroke? 🧠 Discover our poster explaining the mode of action of our lead drug candidate BIOX-101, the potential impact and key findings in a ICH mouse model. We are still at the Brain Innovation Days today for more insights. Not in Brussels today? Head over to our website for more information 👉 bioxodes.com Poster credits to Stéphanie Demoulin, Valérie Pireaux, Marc Dechamps, Hans Warrinnier, Edmond Godfroid #strokecare #voiceofstroke #braininnovationdays #clinicaltrials

🌟 Full house at the Brain Innovation Days in Brussels! We are thrilled to announce that our Chief Medical Officer, Dr. Hans Warrinnier, had the honor of delivering an elevator pitch, presenting the groundbreaking potential of BIOX-101 to investors and key stakeholders. Being chosen to pitch among a select group is a true privilege, reflecting the significance of the unmet medical need we’re addressing. BIOX-101 is our unique therapeutic solution designed to tackle critical gaps in patient care. With a clear focus on addressing challenging medical conditions where there are limited or no existing treatments, BIOX-101 represents hope for patients and healthcare providers alike. In addition to the pitch, we are proud to share that Bioxodes was also selected to showcase a poster at the conference, highlighting our recent developments. Our CEO, Marc Dechamps, and CMO, Dr. Hans Warrinnier, are onsite today and tomorrow to engage with attendees and discuss the science and strategy behind our innovation. We look forward to sharing more about our journey to advance neurological health and are grateful to #BrainInnovationDays for this opportunity. #HealthcareInnovation #Biotech #StrokeCare #BIOX101 #Bioxodes #BrainHealth

🌍 Today, on World Stroke Day, Bioxodes reaffirms its commitment to the global fight against stroke 🌍 We’re proud to stand with the worldwide community to spotlight the urgent need for better stroke prevention, treatment, and care. At Bioxodes, our mission goes beyond awareness—we’re taking action through innovation. With our groundbreaking Phase 2a clinical study, we’re dedicated to developing BIOX-101, a novel treatment with the potential to transform outcomes for hemorrhagic stroke patients. Stay tuned as we share insights from different stakeholders, highlighting the strides we’re making toward a future with improved solutions for stroke care. World Stroke Day is an excellent initiative driven by the World Stroke Organization #WorldStrokeDay #StrokeAwareness #Bioxodes #InnovationInHealth

As we approach the Brain Innovation Days in Brussels on November 13-14, we’re gearing up to share our latest insights into intracerebral hemorrhage (ICH) treatment. Dr. Hans Warrinnier, our Chief Medical Officer, will present Bioxodes’ pioneering research in this field through our selected poster presentation. Looking forward to connecting with the community and advancing conversations on ICH innovations! Connect with our CEO Marc Dechamps and our CMO Hans Warrinnier who will be representing Bioxodes! 📍 Details: Bioxodes Events Page https://lnkd.in/ea8np5bM #BrainInnovationDays #Bioxodes #BrainHealth #StrokeResearch #Voiceofstroke

✨Bioxodes topped a list of six biotech companies whose medicines are derived from animals in an article in Labiotech.eu, Europe’s leading biotech news website. “Some of the most exciting therapies in the future could come from animals,” the article concluded. At Bioxodes, we couldn’t agree more! The saliva of the tick contains proteins which Bioxodes uses in its BIOX-101 therapy for hemorrhagic stroke, an often deadly condition. BIOX-101 has anti-clotting and anti-inflammatory properties, without causing further bleeding. The article also listed Celtic Biotech Ltd, which uses the venom of the rattlesnake to battle cancer, and Soricimed Biopharma Inc., whose cancer drugs are derived from the saliva of the northern short-tailed shrew, a venomous mammal from Northern America. Bioxodes is enrolling the first 16 intracerebral hemorrhagic stroke (ICH) patients in a Phase 2a study with BIOX-101, and expects interim results in the first quarter of 2025. The study is taking place across 10 stroke centres in Belgium, and is led by Prof Robin Lemmens, a world-leading stroke authority, and head of clinic at the University Hospital Leuven, UZ Leuven. 📌 To read the article, click here 👉 https://lnkd.in/exvKvfdx 📌 For more about Bioxodes, please go to our website 👉 www.bioxodes.com. #Biotech #Innovation #Healthcare #LifeSciences #Belgium #ticksaliva #stroke #voiceofstroke

🌍 Building on our commitment to #WorldStrokeDay, we’re excited to share insights from Professor Robin Lemmens of UZ Leuven 🌍 As the lead investigator in our clinical trials for BIOX-101, Professor Lemmens discusses why this drug could be a game-changer for hemorrhagic stroke patients, a condition with limited treatment options. Learn more about how BIOX-101 aims to improve patient outcomes and address this global health challenge.   ❓ Professor Lemmens, you are leading the Bioxodes clinical studies into a new drug, BIOX-101, which can help patients with hemorrhagic stroke, or brain bleed. As a world authority, as well as a practitioner, why do you think this is such an important step for patients❓ 💬 "BIOX-101 is the first drug candidate for Bioxodes, which is developing a cure for ICH, the most common form of hemorrhagic stroke, addressing a major unmet medical need. Current treatment options for hemorrhagic stroke are severely limited, and unfortunately, outcomes for patients are often poor due to secondary effects that arise after the initial stroke. BIOX-101 is designed to mitigate these effects, offering hope for significantly improved outcomes." ❓Is stroke a frequent and serious issue globally❓ 💬 "Absolutely. Stroke is the second leading cause of death worldwide, and hemorrhagic stroke accounts for 40% of these fatalities. It’s a devastating condition with limited treatment options, making innovative solutions like BIOX-101 critical in addressing this public health crisis." ❓How does BIOX-101 work, and what makes it different from existing treatments❓ 💬 "BIOX-101 targets the secondary effects of hemorrhagic stroke without increasing the risk of new bleeding. What’s unique about BIOX-101 is that it’s based on a naturally occurring protein from tick saliva, which has powerful anti-clotting and anti-inflammatory properties. While it doesn’t prevent a stroke, BIOX-101 could potentially improve patient outcomes by addressing complications that occur after the stroke.” #GreaterThanStroke #WorldStrokeDay #StrokeAwareness #Bioxodes

Nous recrutons (#hiring) pour le poste de Study Nurse (Belgium). Postulez dès maintenant ou partagez ce post avec votre réseau.